Startseite Evaluation of the iChem® Velocity™ Urine Chemistry Analyzer in a hospital routine laboratory
Artikel
Lizenziert
Nicht lizenziert Erfordert eine Authentifizierung

Evaluation of the iChem® Velocity™ Urine Chemistry Analyzer in a hospital routine laboratory

  • Peter Hoffmann EMAIL logo , Christina Hoffmann , Reinhard Ziebig und Mathias Zimmermann
Veröffentlicht/Copyright: 3. Februar 2011
Veröffentlichen auch Sie bei De Gruyter Brill

Abstract

Background: The novel urine chemistry analyzer iChem Velocity (IRIS Diagnostics) offers improved urinalysis automation options through integration with the well-established iQ200 urine microscopy analyzer. In the course of optimizing the workflow in our hospital routine laboratory, we evaluated the performance of the iChem Velocity.

Methods: A total of 257 random urine samples were analyzed with the iChem Velocity, iQ200, Clinitek Atlas (Siemens Healthcare Diagnostics) and by manual microscopy.

Results: Depending on the parameter, 93% (hemoglobin) to 100% (urobilinogen), the iChem Velocity and Clinitek Atlas results agreed within the same rank or within one level of difference. The Clinitek Atlas featured a higher sensitivity for hemoglobin (area under the curve 0.86) and leukocyte esterase (area under the curve 0.85) compared with the iChem Velocity (area under the curve for hemoglobin 0.73, leukocytes 0.78). Imprecision was highest for hemoglobin and leukocytes in a pathological sample pool. While the precision of the Clinitek Atlas for hemoglobin measurements was superior, the iChem Velocity was more precise in analyzing protein and pH.

Conclusions: Through urinalysis automation with the iChem Velocity and iQ200, we achieved a reduction of hands-on time by 89%. The sensitivity of this new system should be further improved through ongoing development.


Corresponding author: Peter Hoffmann, Charité Universitätsmedizin Berlin, Institut für Laboratoriumsmedizin und Pathobiochemie, Augustenburger Platz 1, 13353 Berlin, Germany Phone: +49 30 450569034, Fax: +49 30 450569900

Received: 2010-6-29
Accepted: 2010;-10-1
Published Online: 2011-02-3
Published in Print: 2011-03-01

©2011 by Walter de Gruyter Berlin New York

Artikel in diesem Heft

  1. Editorial
  2. Biomarkers of neurodegenerative diseases
  3. Reviews
  4. CSF biomarkers in neurodegenerative diseases
  5. Tau and p-tau as CSF biomarkers in dementia: a meta-analysis
  6. Amyloid β (Aβ) and phospho-tau (p-tau) as diagnostic biomarkers in Alzheimer's disease
  7. The effect of apolipoprotein E (ApoE) genotype on biomarkers of amyloidogenesis, tau pathology and neurodegeneration in Alzheimer's disease
  8. Advanced glycation endproducts as gerontotoxins and biomarkers for carbonyl-based degenerative processes in Alzheimer's disease
  9. Parkinson's disease – the continuing search for biomarkers
  10. α-Synuclein in Parkinson disease and other neurodegenerative disorders
  11. S100B protein in neurodegenerative disorders
  12. Inflammatory and structural biomarkers in acute traumatic spinal cord injury
  13. Homocysteine: a biomarker in neurodegenerative diseases
  14. Editorial
  15. ROMA or death: advances in epithelial ovarian cancer diagnosis
  16. Review
  17. Laboratory testing for the antiphospholipid syndrome: making sense of antiphospholipid antibody assays
  18. General Clinical Chemistry and Laboratory Medicine
  19. Quality indicators and specifications for key analytical-extranalytical processes in the clinical laboratory. Five years’ experience using the Six Sigma concept
  20. Determination of oxidative and occupational stress in palliative care workers
  21. Effect of cigarette smoking on plasma homocysteine concentrations
  22. Erythrocyte membrane protein analysis by sodium dodecyl sulphate-capillary gel electrophoresis in the diagnosis of hereditary spherocytosis
  23. Evaluation of hematological parameters on admission for the prediction of 7-day in-hospital mortality in a large trauma cohort
  24. Platelet function testing in hirudin and BAPA anticoagulated blood
  25. Evaluation of the iChem® Velocity™ Urine Chemistry Analyzer in a hospital routine laboratory
  26. Crystalluria: prevalence, different types of crystals and the role of infrared spectroscopy
  27. Cancer Diagnostics
  28. The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful?
  29. Evaluation of the accuracy of serum human epididymis protein 4 in combination with CA125 for detecting ovarian cancer: a prospective case-control study in a Korean population
  30. Cardiovascular Diseases
  31. APOA5 −1131T/C polymorphism is associated with coronary artery disease in a Chinese population: a meta-analysis
  32. Assessment of the nickel-albumin binding assay for diagnosis of acute coronary syndrome
  33. Letters to the Editor
  34. AGER gene -374T>A (rs1800624) polymorphism is not associated with the severity of non-diabetic coronary artery disease in Han Chinese
  35. Some lessons learned from using medium scale genotyping techniques in pharmacogenetic research
  36. Improved neopterin ELISA kit: a good compromise between HPLC results and clinical practice
  37. Cross-reactivity of 25-hydroxy vitamin D2 from different commercial immunoassays for 25-hydroxy vitamin D: an evaluation without spiked samples
  38. Modulated human maternal and premature neonatal erythrocyte membrane enzyme activities in relation to the mode of delivery: in vitro restoration with L-Carnitine
Heruntergeladen am 7.9.2025 von https://www.degruyterbrill.com/document/doi/10.1515/CCLM.2011.065/html
Button zum nach oben scrollen